## **Product** Data Sheet

## **Anticancer agent 139**

**Cat. No.:** HY-149388 **CAS No.:** 2954795-29-8

 $\label{eq:molecular-formula:} \textbf{Molecular Formula:} \qquad \textbf{C}_{16}\textbf{H}_{12}\textbf{F}_{3}\textbf{N}_{3}\textbf{O}$ 

Target: Microtubule/Tubulin

Pathway: Cell Cycle/DNA Damage; Cytoskeleton

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

319.28

## **BIOLOGICAL ACTIVITY**

Description

Molecular Weight:

Anticancer agent 139 (Compound 6h) has potent anticancer activity. Anticancer agent 139 displayed a  $\pi$ -cationic interaction with the residue Lys352 of Tublin. Anticancer agent 139 has good anticancer activity against SNB-19, OVCAR-8, and NCI-H40 with PGIs of 86.61, 85.26, and 75.99, respectively. Anticancer agent 139 also has moderate anticancer activity against HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 with PGIs of 67.55, 65.46, 59.09, 59.02, 57.88, 56.88, 56.53, 56.4, and 51.88 respectively<sup>[1]</sup>.

## **REFERENCES**

[1]. Mohit Agarwal, et al. Design, Synthesis, ADME, and Anticancer Studies of Newer N-Aryl-5-(3,4,5-Trifluorophenyl)-1,3,4-Oxadiazol-2-Amines: An Insight into Experimental and Theoretical Investigations. ACS Omega 2023, 8, 30, 26837-26849.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA